EPRX logo

EUPRAXIA PHARMACEUTICALS INC

EPRXNASDAQ
🏆 #3470 by market capEarnings Nov 3US Equity
$104.73▲ $7.30 (+6.97%)
Simulated price
🔔
Track EPRX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.0%
7d▲ 1119.2%
14d▲ 1194.6%
30d▲ 1471.3%
ytd▲ 1278.9%
1y▲ 1734.2%
🏦Market Cap
$276M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
36
Weak

Trading Snapshot

Day Range
$104.28 – $106.11
52-Week Range
$5.25 – $9.32
Volume
$1.77B
Avg Volume
$1.91B
Shares Outstanding
33.5M
Next Earnings
Dec 4, 2026

Fundamentals Snapshot

Annual Revenue
$18M
Last Q Revenue
$5M
P/E Ratio
-8.1
P/S Ratio
0.0x
EPS (TTM)
$-0.75
Dividend Yield
0.00%
Dilution (1yr)
+45.7%

Why Investors Own EPRX

  • ✓High-growth profile — revenue up -4.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 68% gross margin and 17% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

EPRX logo

EUPRAXIA PHARMACEUTICALS INC

EPRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$38M▲ +42.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$30M▼ −1.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
51.9M▲ +45.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$80M▲ +$47M YoY
StockOtter · stockotter.space

About EUPRAXIA PHARMACEUTICALS INC

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
36/100

Analyst Ratings

ⓘ
Consensus
Buy
11 analysts
Strong Buy4
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
CNBC·2h ago

EUPRAXIA PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift EPRX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

EUPRAXIA PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.